Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 6
2005 6
2006 4
2007 7
2008 10
2009 9
2010 6
2011 4
2012 5
2013 6
2014 7
2015 12
2016 12
2017 11
2018 4
2019 8
2020 12
2021 13
2022 13
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Takhar P, Geirnaert M, Gavura S, Beca J, Mercer RE, Denburg A, Muñoz C, Tadrous M, Parmar A, Dionne F, Boehm D, Chambers C, Craig E, Trudeau M, Cheung MC, Houlihan J, McDonald V, Pechlivanoglou P, Taylor M, Wasylenko E, Wranik WD, Chan KKW. Takhar P, et al. Among authors: trudeau m. Curr Oncol. 2024 Apr 1;31(4):1876-1898. doi: 10.3390/curroncol31040141. Curr Oncol. 2024. PMID: 38668044 Free PMC article.
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.
Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, Califaretti N, Poirier B, Ardizzoia A, Hoenig A, Lex B, Mouret-Reynier MA, Giesecke D, Isambert N, Masetti R, Pitre L, Wrobel D, Augereau P, Milani M, Rask S, Solbach C, Pritzker L, Noubir S, Parissenti A, Trudeau ME. Cazzaniga ME, et al. Among authors: trudeau me. JNCI Cancer Spectr. 2024 Jan 4;8(1):pkad107. doi: 10.1093/jncics/pkad107. JNCI Cancer Spectr. 2024. PMID: 38113421 Free PMC article.
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
Parmar A, Dai WF, Dionne F, Geirnaert M, Denburg A, Ahuja T, Beca J, Bouchard S, Chambers C, Hunt MJ, Husereau D, Lungu E, McDonald V, Mercer RE, Mitera G, Muñoz C, Naipaul R, Peacock S, Potashnik T, Tadrous M, Takhar P, Taylor M, Trudeau M, Wasney D, Gavura S, Chan KKW. Parmar A, et al. Among authors: trudeau m. Curr Oncol. 2023 Mar 28;30(4):3776-3786. doi: 10.3390/curroncol30040286. Curr Oncol. 2023. PMID: 37185399 Free PMC article.
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. Chan A, et al. Among authors: trudeau m. Breast. 2023 Feb;67:94-101. doi: 10.1016/j.breast.2022.12.003. Epub 2022 Dec 14. Breast. 2023. PMID: 36702070 Free PMC article.
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
Habbous S, Tai X, Beca JM, Arias J, Raphael MJ, Parmar A, Crespo A, Cheung MC, Eisen A, Eskander A, Singh S, Trudeau M, Gavura S, Dai WF, Irish J, Krzyzanowska M, Lapointe-Shaw L, Naipaul R, Peacock S, Yeung L, Forbes L, Chan KKW. Habbous S, et al. Among authors: trudeau m. JAMA Netw Open. 2022 Aug 1;5(8):e2225118. doi: 10.1001/jamanetworkopen.2022.25118. JAMA Netw Open. 2022. PMID: 35917122 Free PMC article.
147 results